Am J Clin Microbiol Antimicrob | Volume 4, Issue 1 | Research Article | Open Access
Senay Coskun1*, Bulent Guzel1, Timucin Imdadoglu2, Tunc Tuncer3, Aysenur Ozdil4 and Sirin Guven2
1Department of Pediatrics, Division of Neonatology, University of Health Science, Prof. Dr. Ilhan Varank
Sancaktepe Hospital, Turkey
2Department of Pediatrics, University of Health Science, Prof. Dr. Ilhan Varank Sancaktepe Hospital, Turkey
3Department of Pediatrics, Division of Cardiology, University of Health Science, Prof. Dr. Ilhan Varank Sancaktepe
Hospital, Turkey
4Department of Public Health, Istanbul University, Turkey
*Correspondance to: Senay Coskun
Fulltext PDFObjective: Despite the increased number of newborns with COVID-19, data on newborns are still scant, and new symptoms and complications continue to be reported. We want to share our own data regarding newborns with COVID-19. Methods: This retrospective single center study was performed in a tertiary pandemic center in Istanbul. The medical records of hospitalized newborns due to COVID-19 from March 17th to December 31st, 2020 were reviewed. The demographic characteristic, the clinical course, complications, and the treatment were recorded. The babies were divided into two groups according to the presence or absence of cardiac complications. The two groups were compared. Short-term follow-up results were presented. Results: 18 newborns were hospitalized during the study period. Most of the newborns had a mild disease. Cardiac complications developed in 3 newborns (16.6%). Two newborns who had clinically suspected myocarditis and myocardial injury were treated with intravenous immunoglobulin and ibuprofen. Baby with SVT developed adenosine-resistant arrhythmia that was controlled only with dual prophylactic medications. All 3 babies were hemodynamically stable. In follow-up the baby with SVT become 8 months old and no attack was observed. Increased troponin levels in babies with myocardial injury gradually returned to normal range for age in 3 and 4 months. When the two groups were compared, it was seen that the nasopharyngeal positive SARS-CoV-2 PCR test became negative in a longer time (days) in patients with cardiac complications (22.3 ± 5.5 vs. 7.87 ± 0.92, p=0.007). Conclusion: Most newborns had a mild disease. In this study, it was observed that newborns with COVID-19 may also have cardiac arrhythmia and myocardial damage. A long-term positive PCR test may be related to the complicated clinical course in newborns. The long-term consequences are unknown and outpatient follow-up is necessary. Keywords: Newborns, Cardiac manifestations, Follow
Covid-19; Covid; Corona Virus; Coronavirus disease 2019,Newborns, Cardiac manifestations, Follow up, Coronavirus infections, COVID-19
Coskun S, Guzel B, Imdadoglu T, Tuncer T, Ozdil A, Guven S. Tertiary Pandemic Center Experience: Characteristics, Clinical Course, Complications and Treatment of Newborns with COVID-19 and their Cardiac Manifestations. Am J Clin Microbiol Antimicrob. 2021; 4(1): 1050..